Shh-Ang-Tie2: A new therapeutic target for ocular angiogenesis.

Shh-Ang-Tie2：眼部血管生成的新治疗靶点。

• 批准号: 21791704
• 负责人: MIYAMOTO Takeshi
• 金额: $ 2.66万
• 依托单位: Wakayama Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21791704/
• 关键词: 眼病理学; ソニックヘッジホッグ; 血管新生; アンギオポイエチン; TIE2; マクロファージ; VEGF; NF kappa B; PGE2

Ocular neovascularization occurs in various diseases like wound healing, ischemic, age related macular degeneration, etc. Sever ocular neovascularization cases visual loss. Anti VEGF drugs are sometimes used for AMD. But in the other desease, we have no effective method to treat the ocular neovasclarizaiton. Angiopoietin is one of the angiogenic factors that are induced by Shh signals. In the laser induced choriodal neovasucularizaiton model in rat, Shh and Gli3, the Shh related signal trunsducion molecule, were immunohistochemically positive in the retinal pigment epithelium and retina around the laser spot. Shh may have an important role in the choroidal neovascularization via Ang expression. And conjunctibal injection of cyclopamin, Shh inhibitor, suppressed the choroidal neovasucularization. Shh may be aneffective target to treat the ocular neovascularization.

眼部新生血管发生于各种疾病中，如创伤愈合、缺血性、年龄相关性黄斑变性等，严重者可导致视力下降。抗VEGF药物有时用于AMD。但在其他疾病中，我们没有有效的治疗方法来治疗眼部新生血管。血管生成素是由Shh信号诱导的血管生成因子之一。在激光诱导的大鼠脉络膜新生血管视网膜病变模型中，Shh和Shh相关信号传导分子Gli3在视网膜色素上皮和激光光斑周围的视网膜中呈免疫化学阳性。Shh可能通过Ang的表达在脉络膜新生血管形成中发挥重要作用。结膜注射Shh抑制剂cyclopamin可抑制脉络膜新生血管形成。Shh可能是治疗眼部新生血管的有效靶点。